Exploring the activity of the enzyme 11β-hydroxylase in the polycystic ovary syndrome

References

[1] Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obest Gynecol. 1935;29:181–91.10.1016/S0002-9378(15)30642-6Search in Google Scholar

[2] Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif AG, Haseltine F, editors. Polycystic ovary syndrome. Baston: Blackwall Scientific; 1992: 377–84.Search in Google Scholar

[3] The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.10.1016/j.fertnstert.2003.10.004Search in Google Scholar

[4] Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Androgen Excess Society. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91:4237–45.10.1210/jc.2006-0178Search in Google Scholar

[5] Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745–9.10.1210/jc.2003-032046Search in Google Scholar

[6] de Medeiros SF, Yamamoto MMW, de Medeiros MAS, Barbosa JS, Norman RJ. Should subclinical hypothyroidism be an exclusion criterion for the diagnosis of polycystic ovary syndrome? J Reprod Infertil. 2017a;18:242–50.Search in Google Scholar

[7] Payne HA, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. Endocr Rev. 2004;25:947–70.10.1210/er.2003-0030Search in Google Scholar

[8] de Medeiros SF, Gil-Junior AB, Barbosa JS, Isaías ED, Yamamoto MMW. New insights into steroidogenesis in normo-and hyperandrogenic polycystic ovary syndrome patients. Arq Bras Endocrinol Metabol. 2013;57:437–44.10.1590/S0004-27302013000600005Search in Google Scholar

[9] Carmina E, Malizia G, Pagano M, Janni A. Prevalence of late-onset 11 beta-hydroxylase deficiency in hirsute patients. J Endocrinol Invest. 1988;11:595–8.10.1007/BF03350188Search in Google Scholar

[10] Sahin Y, Keleştimur F. 17-Hydroxyprogesterone responses to gonadotrophin-releasing hormone agonist buserelin and adrenocorticotrophin in polycystic ovary syndrome: investigation of adrenal and ovarian cytochrome. 1997;12:910–13.10.1093/humrep/12.5.910Search in Google Scholar

[11] Gibson M, Lackritz R, Schiff I, Tulchinsky D. Abnormal adrenal responses to adrenocorticotropic hormone in hyperandrogenic women. Fertil Steril. 1980;33:43–48.10.1016/S0015-0282(16)44475-4Search in Google Scholar

[12] Turcu AF, Auchus RJ. Clinical significance of 11-oxygenated androgens. Curr Opin Endocrinol Diabetes Obes. 2017;24:252–9.10.1097/MED.0000000000000334Search in Google Scholar PubMed PubMed Central

[13] Ditkoff EC, Fruzzetti F, Chang L. The impact of estrogen on adrenal androgen sensitivity and secretion in polycystic ovary syndrome. J Clin Endocrinol Metab. 1995;80:603–7.10.1210/jcem.80.2.7852527Search in Google Scholar

[14] de Medeiros SF, Yamamoto MMW. Differential activity of the corticosteroidogenic enzymes in normal cycling women and women with polycystic ovary syndrome. Rev Endocrinol Metab Disord. 2019;20:3–13.10.1007/s11154-019-09482-3Search in Google Scholar PubMed

[15] de Medeiros SF, Barbosa JS, Yamamoto MMW. Comparison of steroidogenic pathways among normoandrogenic and hyperandrogenic polycystic ovary syndrome patients and normal cycling women. J Obstet Gynaecol Res. 2015;41:254–63.10.1111/jog.12524Search in Google Scholar PubMed

[16] de Medeiros SF, Ormond CM, de Medeiros MAS, de Souza Santos N, Banhara CR, Yamamoto MMW. Metabolic and endocrine connections of 17-hydroxypregnenolone in polycystic ovary syndrome women. Endocr Connect. 2017b;6:479–88.10.1530/EC-17-0151Search in Google Scholar PubMed PubMed Central

[17] American Diabetes Association. 2 Classification and diagnosis of diabetes. Am Diabetes Assoc. 2017;40(Suppl 1):S11–S24.10.2337/dc17-S005Search in Google Scholar PubMed

[18] Geloneze B, Vasques AC, Stabe CF. BRASMS Investigators, HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome: Brazilian Metabolic Syndrome Study (BRAMS). Arq Bras Endocrinol Metab. 2009;53:281–7.10.1590/S0004-27302009000200020Search in Google Scholar PubMed

[19] Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.10.1007/BF00280883Search in Google Scholar PubMed

[20] Kushnir MM, Rockwood AL, Roberts WL, Pattison EG, Owen WE, Bunker AM, et al. Development and performance evaluation of a tandem mass spectrometry assay for 4 adrenal steroids. Clin Chem. 2006;52:1559–67.10.1373/clinchem.2006.068445Search in Google Scholar PubMed

[21] Legro RS, Schlaff WD, Diamond MP. Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. J Clin Endocrinol Metab. 2010;95:5305–13.10.1210/jc.2010-1123Search in Google Scholar PubMed PubMed Central

[22] Hicks RA, Yee JK, Mao CS, Graham S, Kharrazi M, Lorey F, et al. Precursor-to-product ratios reflect biochemical phenotype in congenital adrenal hyperplasia. Metabolomics. 2014;10:123–31.10.1007/s11306-013-0558-1Search in Google Scholar PubMed PubMed Central

[23] Tieh PY, Yee JKW, Hicks RA, Catherine Shring-May Mao MD, Paul Lee W-N. Utility of a precursor-to-product ratio in the evaluation of presumptive positives in newborn screening of congenital adrenal hyperplasia. J Perinatol. 2017;37:283–7.10.1038/jp.2016.223Search in Google Scholar PubMed PubMed Central

[24] de Medeiros SF, Yamamoto MMW, Bueno HB, Belizario D, Barbosa JS. Prevalence of elevated glycated hemoglobin concentrations in the polycystic ovary syndrome: anthropometrical and metabolic relationship in Amazonian women. J Clin Med Res. 2014;6:6278–86.10.14740/jocmr1829wSearch in Google Scholar

[25] Gambineri A, Forlani G, Munarini A, Tomassoni F, Cognigni GE, Ciampaglia W, et al. Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome. J Endocrinol Invest. 2009;32:210–8.10.1007/BF03346454Search in Google Scholar

[26] Blumenfeld Z, Kaidar G, Zuckerman-Levin N, Dumin E, Knopf C, Hochberg Z. Cortisol-metabolizing enzymes in polycystic ovary syndrome. Clin Med Insights Reprod Health. 2016;10:9–13.10.4137/CMRH.S35567Search in Google Scholar

[27] Deng W, Liu X, Chen X, Wei G, Zeng T, Xie L, Jian-xin Z. A comparison of the climates of the medieval climate anomaly little ice age, and current warm period reconstructed using coral records from the northern South China Sea. J Geophys Res. 2017;122:264–75.10.1002/2016JC012458Search in Google Scholar

[28] Sahin Y, Kelestimur F. The frequency of late-onset 21-hydroxylase and CYP11B1 deficiency in women with polycystic ovary syndrome. Eur J Endocrine. 1997;137:670–4.10.1530/eje.0.1370670Search in Google Scholar

[29] Rothman MS, Carlson NE, Xu M, Wang C, Swerdloff R, Lee P, et al. Reexamination of testosterone, dihydrotestosterone, estradiol and estrone levels across the menstrual cycle and in postmenopausal women measured by liquid chromatography-tandem mass spectrometry. Steroids. 2011;76:177–82.10.1016/j.steroids.2010.10.010Search in Google Scholar

[30] Pall M, Azziz R, Beires J, Pignatelli D. The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Fertil Steril. 2010;94:684–9.10.1016/j.fertnstert.2009.06.025Search in Google Scholar

[31] Carmina E, Gonzalez F, Chang L, Lobo RA. Reassessment of adrenal androgen secretion in women with polycystic ovary syndrome. Obstet Gynecol. 1995;85:971–6.10.1016/0029-7844(95)00065-YSearch in Google Scholar

[32] Doi SA, Al-Zaid M, Towers PA, Scott CJ, AI-Shoumer KA. Steroidogenic alterations and adrenal androgen excess in PCOS. Steroids. 2006;71:751–9.10.1016/j.steroids.2006.05.005Search in Google Scholar PubMed

[33] Trakakis E, Rizos D, Loghis C. The prevalence of non-classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency in Greek women with hirsutism and polycystic ovary syndrome. Endocr J. 2008;55:33–9.10.1507/endocrj.K07-053Search in Google Scholar PubMed

[34] Sharma DC, Forchielli E, Dorfman RI. Inhibition of enzymatic steroid 11β-hydroxylation by androgens. J Biol Chem. 1963;238:572–5.10.1016/S0021-9258(18)81300-XSearch in Google Scholar

[35] Gillis D, Speiser P, Zhou Z, Rosler A. Combined 21-hydroxylase deficiency: patients report and molecular basis. J Pediatr Endocrinol Metab. 2000;13:945–9.10.1515/JPEM.2000.13.7.945Search in Google Scholar

[36] Rosenfield RL, Barnes RB, Cara JF. Dysregulation of cytochrome P450c 17 alpha as a cause of polycystic ovary syndrome. Fertil Steril. 1990;53:785–91.10.1016/S0015-0282(16)53510-9Search in Google Scholar

[37] Atmaca A, Dagdelen S, Erbas T. Follow-up of pregnancy in acromegalic women: different presentations and outcomes. Exp Clin Endocrinol Diabetes. 2006;114:135–9.10.1055/s-2005-873004Search in Google Scholar

[38] Guthrie GP Jr, Wilson EA, Quillen DL, Jawad MJ. Adrenal androgen excess and defective 11β-hydroxylation in women with idiopathic hirsutism. Arch Intern Med. 1982;142:729–35.10.1001/archinte.1982.00340170085017Search in Google Scholar

[39] Bouallouche A, Brerault JL, Fiet J, Julien R, Vermeulen C, Cathelineau G. Evidence for adrenal and/or ovarian dysfunction as a possible etiology of idiopathic hirsutism. Am J Obstet Gynecol. 1983;147:57–63.10.1016/0002-9378(83)90084-4Search in Google Scholar

[40] Eldar-Geva T, Hurwitz A, Vecsei P, Palti Z, Milwidsky A, Rosler A. Secondary biosynthetic defects in women with late-onset congenital adrenal hyperplasia. Engl J Med. 1990;32:855–63.10.1056/NEJM199009273231302Search in Google Scholar PubMed

[41] Keleştimur F, Sahin Y, Ayata D, Tutuş A. The prevalence of non-classic adrenal hyperplasia due to 11 beta-hydroxylase deficiency among hirsute women in a Turkish population. Clin Endocrinol. 1996;45:381–4.10.1046/j.1365-2265.1996.8150825.xSearch in Google Scholar PubMed

[42] Willenberg HS, Bahlo M, Schott M, Wertenbruch T, Feldkamp J, Scherbaum WA. Helpful diagnostic markers of steroidogenesis for defining hyperandrogenemia in hirsute women. Steroids. 2008;73:41–6.10.1016/j.steroids.2007.08.009Search in Google Scholar PubMed

[43] Dolfing JG, Tucker KE, Lem CM, Uittenbogaart J, Verzijl JC, Schweitzer DH. Low 11-deoxycortisol to cortisol conversion reflects extra-adrenal factors in the majority of women with normo-gonadotrophic normo-estrogenic infertility. Human Reprod. 2003;18:333–7.10.1093/humrep/deg082Search in Google Scholar PubMed

[44] Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA. Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. J Clin Endocrinol Metab. 2005;90:2545–9.10.1210/jc.2004-2279Search in Google Scholar PubMed

[45] Baptiste CG, Marie-Claude B, Trottier A, Baillargeon JP. Insulin and hyperandrogenism in women with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2010;122:42–52.10.1016/j.jsbmb.2009.12.010Search in Google Scholar PubMed PubMed Central

[46] Mullins LJ, Peter A, Wrobel N, McNeilly JR, McNeilly AS, Al-Dujaili EA, et al. Cyp11b1 null mouse, a model of congenital adrenal hyperplasia. J Biol Chem. 2009;284:3925–393.10.1074/jbc.M805081200Search in Google Scholar PubMed